Wang Huamao, Jiang Hua, Zhou Min, Xu Zhibing, Liu Shiguo, Shi Bizhi, Yao Xiao, Yao Ming, Gu JianRen, Li Zonghai
Medical School of Fudan University, Shanghai, China.
Cancer Lett. 2009 Jun 28;279(1):30-8. doi: 10.1016/j.canlet.2009.01.019. Epub 2009 Feb 12.
We investigated whether EGFRvIII contributes to tumorigenicity and resistance to 5-FU in HCC cell lines. Our results show that several HCC cell lines have EGFRvIII expression. EGFRvIII-positive HCC cells grew more rapidly and had a lower sensitivity to 5-FU than EGFRvIII-negative HCC cells. For further analysis of the biological characteristics of EGFRvIII, an EGFRvIII or EGFR expression cassette was introduced into the HCC cell line, Huh-7. Compared with Huh-7 cells and Huh7-EGFR cells, Huh7-EGFRvIII not only exhibit significantly increase of cell growth in vitro and in vivo but also show enhanced migration in vitro. Furthermore, 5-FU has significantly lower inhibition effect on Huh7-EGFRvIII cells then on both Huh-7 and Huh7-EGFR cells in vitro and in vivo. Collectively, these results demonstrate that EGFRvIII plays a pivotal role in tumorigenicity and enhanced 5-FU resistance of HCC.
我们研究了表皮生长因子受体III型变异体(EGFRvIII)是否在肝癌细胞系的致瘤性及对5-氟尿嘧啶(5-FU)的耐药性中发挥作用。我们的结果显示,几种肝癌细胞系均有EGFRvIII表达。与EGFRvIII阴性的肝癌细胞相比,EGFRvIII阳性的肝癌细胞生长更快,且对5-FU的敏感性更低。为进一步分析EGFRvIII的生物学特性,将一个EGFRvIII或EGFR表达盒导入肝癌细胞系Huh-7。与Huh-7细胞及Huh7-EGFR细胞相比,Huh7-EGFRvIII不仅在体外和体内均表现出细胞生长显著增加,而且在体外显示出更强的迁移能力。此外,在体外和体内,5-FU对Huh7-EGFRvIII细胞的抑制作用均显著低于对Huh-7和Huh7-EGFR细胞的抑制作用。总体而言,这些结果表明EGFRvIII在肝癌的致瘤性及增强的5-FU耐药性中起关键作用。